Boyds expands Regulatory Affairs team to support growing demand

pharmafile | October 16, 2026 | Appointment | |  Consultancy, Diagnostics, Pharmacy, drug development, life sciences, regulatory affairs 

Vicki Hayes has joined Boyds as Vice President of Regulatory Affairs with Jan Ohotski becoming Director of Regulatory Affairs.  

Hayes brings more than 20 years’ experience in regulatory affairs and joins Boyds from a US biotechnology company, where she was Vice President of Global Regulatory Affairs and Policy. She was previously a Board Director at a regulatory affairs consultancy, where she held several senior regulatory affairs roles, and has also worked at Amgen and Eli Lilly and Company. 

Ohotski joins Boyds from CRO Medpace, where he led the Cell and Gene Therapy team. He began his career as a scientist focused on drug discovery and pharmacology for oncological indications, working in both academia and industry, before moving into regulatory affairs more than ten years ago. He specialises in the clinical development of cell and gene therapies and, at Boyds, will support regulatory affairs activities alongside clinical operations.

Pic: Vicki Hayes, Katherine Bowen (Chief Regulatory Affairs Officer at Boyds) and Jan Ohotski.